Abstract
Eosinophilic gastroenteritis (EGE) is a rare, immune-mediated disorder characterized by pathological eosinophilic infiltration of the gastrointestinal tract. Corticosteroids are the primary treatment for EGE, but managing patients who are corticosteroid-dependent can be challenging. This report describes a 33-year-old female patient with EGE and severe hypereosinophilia, who was corticosteroid-dependent and had been on long-term oral corticosteroids for 5 years with an increasing maintenance dose. The patient achieved effective treatment with omalizumab without adverse reactions. This case provides evidence for the efficacy and safety of omalizumab in patients with corticosteroid-dependent eosinophilic gastroenteritis and severe hypereosinophilia.